**5. Conclusion**

The landscape of treatment for HCC has been fundamentally changed with the advent of immunotherapy. Despite this shift, patients with HCC often have a unique set of circumstances which predisposes them to toxicities related to these drugs. Additionally, the dual roles for immunotherapy and liver transplant in this population can cause complex interactions and potentially devastating complications. Further research to identify other immunotherapeutic treatment modalities is underway. Additionally, more research will be required to better characterize the treatment toxicities and risks associated with transplant.
